Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
ctp-543 save search
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
PMVP | $1.61 -0.62% 250K
|
Commercial Services
|
| O: -1.2%
H: 4.27%
C: 0.61%
tp53 first tumors pharmaceuticals global trial
Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
Published: 2024-02-23 (Crawled : 12:30) - prnewswire.com
ATNM | $6.695 0.38% 130K
|
Health Technology
|
| O: 4.45%
H: 1.85%
C: -2.56%
tp53 astct positive leukemia trial therapy
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023
Published: 2023-12-05 (Crawled : 21:00) - globenewswire.com
STTK | $9.92 -2.07% 220K
|
Health Technology
|
| O: 2.05%
H: 20.1%
C: 20.1%
tp53 review meeting leukemia trial
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
Published: 2023-11-06 (Crawled : 12:00) - prnewswire.com
KPTI | $1.255 -1.95% 460K
|
Health Technology
|
| O: 3.4%
H: 5.47%
C: -4.36%
tp53 cancer study
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
Published: 2023-11-02 (Crawled : 13:00) - prnewswire.com
ATNM | $6.695 0.38% 130K
|
Health Technology
|
| O: 1.29%
H: 3.83%
C: -16.58%
tp53 presentation treatment aml meeting trial
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
Published: 2023-10-12 (Crawled : 17:00) - globenewswire.com
PMVP | $1.61 -0.62% 250K
|
Commercial Services
|
| O: 0.63%
H: 1.88%
C: -47.91%
pc1458 pharmaceuticals tumor tp53
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
RANI | $6.82 12.73% 130K
|
|
| O: 1.46%
H: 4.32%
C: -2.52%
rt-111 ranipill therapeutics study
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Published: 2023-07-25 (Crawled : 19:00) - prnewswire.com
KPTI | $1.255 -1.95% 460K
|
Health Technology
|
| O: -2.52%
H: 12.26%
C: 11.61%
tp53 presentation cancer study
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH
Published: 2022-12-12 (Crawled : 14:00) - biospace.com/
ATNM | $6.695 0.38% 130K
|
Health Technology
|
| O: -1.67%
H: 1.7%
C: 0.0%
tp53 treatment aml trial presentation
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
Published: 2022-08-22 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: -2.2%
H: 1.65%
C: -0.3%
ctp-543 trial presentation
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-08-01 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 12.57%
H: 4.0%
C: -1.83%
topline trial positive
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
Published: 2022-06-07 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 3.25%
H: 5.87%
C: 2.94%
trial results phase 2
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 6.07%
H: 8.26%
C: -13.24%
ctp-543 topline trial positive phase 3
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 2.45%
H: 4.47%
C: 0.3%
ctp-543 als trial phase 3 enroll
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting
Published: 2021-12-14 (Crawled : 13:30) - biospace.com/
ATNM | $6.695 0.38% 130K
|
Health Technology
|
| O: -4.84%
H: 2.03%
C: -7.27%
tp53 als trial phase 1 aml
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: -2.17%
H: 1.85%
C: -0.37%
phase 3 trial enroll
The Patient Recruiting Agency, LLC Announces Enrollment Launched for the CTP-543 THRIVE Clinical Program Investigating Oral Treatment for Moderate to Severe Alopecia Areata
Published: 2021-07-08 (Crawled : 17:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: -2.11%
H: 2.15%
C: -1.08%
treatment enroll
Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit
Published: 2021-07-01 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: -4.02%
drug
Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
Published: 2021-05-27 (Crawled : 12:15) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: -0.25%
H: 2.02%
C: 0.25%
phase 3 trial
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
BSFC | $0.0822 27.64% 75M
|
Manufacturing
RWOD | $10.08 26.05% 5.6M
|
n/a
CHRO | $1.53 24.9% 100K
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.